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A Phase II Randomized Study of Paclitaxel Plus Carboplatin
or Cisplatin against Chemo-Naive Inoperable Non-small
Cell Lung Cancer in the Elderly
Yuh-Min Chen, MD, PhD,* Reury-Perng Perng, MD, PhD,* Chun-Ming Tsai, MD,* and
Jacqueline Whang-Peng, MD†
Abstract: Paclitaxel plus carboplatin (CAR) or cisplatin (CIS) has
shown activity in the treatment of advanced non-small cell lung
cancer (NSCLC). Our aim was to determine whether paclitaxel plus
platinum is an appropriate regimen for chemo-naı¨ve NSCLC in
patients aged 70 years or older. Patients were randomized into
paclitaxel plus CAR or paclitaxel plus CIS treatment arms. Treat-
ment consisted of paclitaxel 160 mg/m2 and carboplatin at AUC 
6 (predicted using measured clearances and the Calvert formula) IV
infusion on day 1 every 3 weeks, or paclitaxel 160 mg/m2 and
cisplatin 60 mg/m2 IV on day 1 every 3 weeks. In total, 81 patients
were enrolled from September 2000 to February 2005, including 40
who received CAR treatment and 41 who received CIS treatment. In
all, 152 cycles of CAR (median, four cycles per patient) and 172
cycles of CIS (median, four cycles per patient) were given. Each arm
had one complete response and 15 partial responses to the treatment,
with overall response rates of 40% and 39%, respectively. Myelo-
suppression was mild in both arms, and there was no statistical
difference between the two arms. Alopecia (P  0.001), peripheral
neuropathy (P  0.017), and fatigue (P  0.001) were more severe
in the CIS treatment arm than in the CAR treatment arm. Median
time to disease progression was 6.6 months in the CAR arm and 6.9
months in the CIS arm. Median survival time was 10.3 months in the
CAR arm and 10.5 months in the CIS arm. In conclusion, paclitaxel
plus CAR or CIS treatment is feasible in elderly patients and has
similar activity. However, paclitaxel plus CAR had less non-hema-
tological toxicity than paclitaxel plus CIS.
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Lung cancer is the leading cause of cancer death in theworld. It is typically a disease of elderly patients, with a
peak incidence at approximately 70 to 80 years of age.1,2
Although elderly patients account for the greater part of the
lung cancer population, they receive treatment less often than
younger patients.3,4 There is also an under-representation of
elderly patients in the chemotherapy clinical trials against
non-small cell lung cancer (NSCLC), especially among those
aged 70 years or older.5
Cisplatin in combination with third-generation chemo-
therapeutic agents has been found to effectively increase
patient survival, although modestly, in randomized trials
and/or meta-analyses.6–8 However, the gastrointestinal, renal,
and neurological toxicities induced by cisplatin can be sig-
nificant and may lead to a perceived negative impact on the
quality of life; thus, they are still a major concern of both
physicians and patients and have led to the view of replacing
cisplatin with carboplatin.7 Carboplatin has less gastrointes-
tinal, renal, and neurological toxicity than cisplatin.7 Theo-
retically, the organ functioning of the elderly patient declines
with age; thus, carboplatin might be a better choice than
cisplatin in this group of patients, except that the myelosup-
pression is higher with carboplatin than cisplatin.7 Indeed, a
retrospective review from England showed that elderly lung
cancer patients treated with carboplatin-based chemotherapy
had better survival than others, whereas cisplatin-based treat-
ment showed only marginal benefit.9
In paclitaxel-based combination chemotherapy, pacli-
taxel plus cisplatin or carboplatin has been shown to be
efficacious against NSCLC.10,11 Many studies have demon-
strated the platelet-sparing effect of paclitaxel used together
with carboplatin, while the dose-limiting toxicity of carbo-
platin was found to be thrombocytopenia.12 Thus, in the
present study, we attempted to study a more promising
platinum-based doublet when combined with paclitaxel treat-
ment in elderly patients with chemo-naive NSCLC.
PATIENTS AND METHODS
This study was conducted according to the existing
rules for good clinical practice, and the protocol was ap-
proved by the local ethics committee. Informed consent was
signed by all patients. Patients with a cytological or histolog-
ical diagnosis of stage IIIb with malignant effusion, or IV
NSCLC; aged 70 years; with no prior chemotherapy or
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immunotherapy; with a performance status of 0 to 2 on the
World Health Organization (WHO) scale; with bidimension-
ally measurable disease; and with an adequate bone marrow
reserve and a white blood cell count 4000/mm3, platelets
100,000/mm3, and hemoglobin 10 g/dl, were eligible for
the study. Patients with signs or symptoms of brain metasta-
ses, inadequate liver function (serum bilirubin 1.5 times
and alanine aminotransferase/aspartate transaminase 3
times upper limit normal), or inadequate renal function (se-
rum creatinine1.5 times upper limit normal) were excluded
from the study. Patients were randomized into the paclitaxel
plus carboplatin (CAR) or paclitaxel plus cisplatin (CIS)
treatment arm by an outside center not involved in the study,
with staging and performance status as stratification factors.
Initial work-up included the documentation of the pa-
tient’s history, a physical examination, and a performance
score. A complete blood cell count, urinalysis, serum bio-
chemistry profile, electrocardiograph, chest roentgenography,
whole-body bone scan, brain computed tomographic scan,
and chest computed tomographic scan (including liver and
adrenal glands) were also performed.
Paclitaxel 160 mg/m2 was given as a 3-hour IV infu-
sion, followed by carboplatin at AUC  6 (predicted using
measured clearances and the Calvert formula) IV for 1 hour
on day 1 of every 3 weeks in the CAR arm, or paclitaxel 160
mg/m2 IV on day 1 and cisplatin 60 mg/m2 IV for 1 hour on
day 1 of every 3 weeks in the CIS arm. The maximal number
of cycles that were planned for patients enrolled in the study
was six, unless there was disease progression, intolerable
toxicities, or patient refusal. All patients received dexameth-
asone (10 mg IV at –12 and –6 hours), cimetidine (300 mg
IV), and diphenhydramine (50 mg IV) before paclitaxel
administration. In addition, adequate hydration, and granis-
etron and metopropramide were administered in the CIS and
CAR arms, respectively, as anti-emetics.
For dose adjustments in the subsequent cycle, a 50%
reduction in the initial dose of paclitaxel and an 80% reduc-
tion in the initial dose of carboplatin or cisplatin were
instituted when the patient experienced grade 4 neutropenia
or thrombocytopenia. This more marked than usual dose
modification was based on the concept of “do no harm and
safety first” with respect to the elderly patients. Subsequent
escalation of the original dosage was allowed providing the
patient tolerated the doses given at the 50% level, followed
by the 75% level. In the area of non-hematological toxicities,
patients were excluded from further study if they experienced
grade 3 or worse neuropathy.
A complete blood cell count was repeated before every
injection and during the nadir period (day 9 to day 11 after
chemotherapy). Serum biochemistry analysis was performed
before every course of chemotherapy and during the course,
if clinically indicated. The study was designed to enroll at
least 35 qualified patients in each arm. This calculation
assumes that the true moderate to severe (grades 2 to 4)
toxicity induced by the more toxic regimen was 10% higher
than that of a safer regimen in terms of specific toxicity items;
peripheral neuropathy was the primary end point in the
present study. The use of this specific toxicity item, instead of
response rate, which is usually used as the primary end point
in phase II studies, was based on the fact that paclitaxel plus
carboplatin or cisplatin has been found to have similar effi-
cacy or survival benefit in non-elderly patients with NSCLC
in studies such as the ECOG-1594.13 Thus, in the present
study, we focused on toxicity that could be more severe in
degree or more frequent in elderly patients, instead of the
response rate. We assumed that the safer regimen had 15%
grade 2 to 4 peripheral neuropathy and that the toxic regimen
had 25% grade 2 to 4 peripheral neuropathy, with a power of
0.85 and a P value of 0.05, and that each treatment group
required at least 35 qualified patients.14
Response and study drug-related toxicities were evalu-
ated according to WHO criteria.15 Patient responses were
reevaluated after three cycles of treatment and when the
patient was off study. All adverse events were recorded
regardless of whether they were thought to be the result of
chemotherapy.
Overall survival and time to disease progression were
analyzed using the Kaplan-Meier estimation method. Time to
disease progression was calculated from the date of initiation
of treatment to the date of disease progression or death. If
disease progression had not occurred by the time of this analysis,
progression-free survival was considered censored at the time of
the last follow-up. Survival time was measured from the date of
initiation of treatment to the date of death. If death had not
occurred, survival time was considered censored at the last
follow-up. All comparisons of response rates and toxicity inci-
dences were performed by using the ANOVA test.
RESULTS
From September 2000 to February 2005, 81 patients
were entered into the study, including 40 patients randomly
assigned into the CAR arm and 41 into the CIS arm. Patient
ages ranged from 70 to 87 years, with mean ages of 76 years
in the CAR arm and 75 years in the CIS arm. The clinical
characteristics of these patients are listed in Table 1. There
was no significant difference in clinical characteristics be-
tween the two arms of treatment, except that all female
patients were randomized into the CIS arm. Under the prin-
ciple of intent to treat, all patients were assessable for toxicity
profile and treatment response.
A total of 324 cycles of paclitaxel-based treatment was
administered, including 152 cycles in the CAR arm and 172
cycles in the CIS arm. The mean and median number of
treatment cycles per patient was 3.8 and 4 in the CAR arm
and 4.2 and 4 in the CIS arm, respectively (Table 1).
After three cycles of treatment, each arm had one
patient with a complete response and 15 patients with a
partial response, with an overall response rate of 40% (95%
CI, 24.8%–55.2%) in the CAR arm and 39% in the CIS arm
(95% CI, 24.1%–53.9%) (Table 2). The disease control rate
(patients with a complete response, partial response, and
stable disease) was higher in the CIS arm (P  0.225).
The median time to disease progression was 6.6 months
in the CAR arm and 6.9 months in the CIS arm (Figure 1).
The median survival of the entire study population was 10.5
months (95% CI, 3.3–17.7 months), with a 1-year survival
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rate of 48.6%. The median survival time was 10.3 months in
the CAR arm and 10.5 months in the CIS arm. The 1-year
survival rate was 49.7% in the CAR arm and 47.1% in the
CIS arm (Figure 2).
The treatment-related toxicities were mild in degree,
mainly hematological, and easy to manage (Table 3). The
incidence of WHO grade 3 or 4 hematological toxicity was:
leukopenia 15%, anemia 12.5%, and thrombocytopenia 7.5%
in the CAR arm; and leukopenia 4.9%, anemia 9.8%, and
thrombocytopenia 2.4% in the CIS arm. There was no statis-
tically significant difference in hematological toxicities be-
tween the two treatment arms. There were several other
non-hematological toxicities (Table 4). Peripheral neuropa-
thy, fatigue, and alopecia were more severe in the CIS arm
than in the CAR arm (P  0.017, 0.001, and 0.001,
respectively), especially grade 2 peripheral neuropathy,
which occurred in 53.7% of patients receiving CIS treatment
but in only 17.5% of patients in the CAR arm.
DISCUSSION
It has been shown that age has an impact on the
treatment of NSCLC. The use of paclitaxel plus cisplatin has
proven to be a well-tolerated and quite active regimen, with
a 1-year survival of approximately 40% in stage IV patients
aged less than 70 years.16 Paclitaxel plus non-cisplatin com-
binations, such as paclitaxel plus carboplatin, may prove to be
reasonable alternatives for patients with NSCLC who cannot
tolerate cisplatin and for patients with a compromised per-
formance status and organ function, such as renal function
impairment or congestive heart failure. The response rate and
median survival in phase II studies of paclitaxel plus carbo-
platin in patients aged less than 70 years ranged from 30 to
45% and 38 to 55 weeks, respectively.17–20 The response rate
TABLE 1. Characteristics of 81 Elderly Patients
Patient n (%)
Variable CAR (n  40) CIS (n  41) P value
Age mean (range) 76 (70–84) 75 (70–87)
Sex 40 (100) 35 (85.4) 0.012
Male
Female 0 6 (14.6)
Performance status 1 (2.5) 3 (7.3) 0.407
0
1 20 (50) 21 (51.2)
2 19 (47.5) 17 (41.5)
Stage 7 (17.5) 5 (12.2) 0.508
IIBw
IV 33 (82.5) 36 (87.8)
Histology 16 (40) 23 (56.1) 0.612
Adenocarcinoma
Squamous cell carcinoma 16 (40) 7 (17.1)
NSCLC, type not specified 8 (20) 11 (26.8)
Cycles completed 152 172 0.299
Total
Mean 3.8 4.2
Median 4 4
CAR, paclitaxel plus carboplatin; CIS, paclitaxel plus cisplatin; NSCLC, non-small
cell lung cancer.
TABLE 2. Overall Response Rate of the 81 Elderly Patients
(Intention to Treat)
Patients n (%)
CAR (n  40) CIS (n  41) P value
Overall response 16 (40) 16 (39) 0.93
Complete response 1 (2.5) 1 (2.4)
Partial response 15 (37.5) 15 (36.6)
Stable disease 15 (37.5) 20 (48.8)
Progressive disease 6 (15) 5 (12.2)
Unevaluable 3 (7.5) 0
Control ratea 77.5 87.8 0.225
CAR, paclitaxel plus carboplatin; CIS, paclitaxel plus cisplatin.
aIncluding complete response, partial response, and stable disease.
FIGURE 1. Time to disease progression among 81 elderly
patients treated with paclitaxel-based regimens. The median
time to disease progression was 6.6 months in the paclitaxel
plus carboplatin arm and 6.9 months in the paclitaxel plus
cisplatin arm (  censor).
FIGURE 2. Survival curve for 81 elderly patients treated
with paclitaxel-based regimens. The median survival was
10.3 months in the paclitaxel plus carboplatin arm and 10.5
months in the paclitaxel plus cisplatin arm (  censor).
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and median survival of our elderly patients who received
paclitaxel plus cisplatin or carboplatin were also within the
range of studies involving younger patients.
Paclitaxel plus cisplatin was found to have a better
response rate than paclitaxel plus carboplatin in the four-arm
ECOG-1594 study, although there was no statistically signif-
icant difference. In contrast, less toxicity and slightly better
median and 1-year survival was found in patients receiving
paclitaxel plus carboplatin treatment, although also with no
statistically significant difference.13 Most patients in the
ECOG-1594 study were younger than ours, and their perfor-
mance status was better than that of ours. However, our
patients had a better response rate and survival. A Japan-
SWOG common-arm analysis of paclitaxel plus carboplatin
treatment also showed a significant difference in toxicity
profiles and survival between Japanese and American pa-
tients.21 The racial difference that seems to exist between
Caucasian and East Asian populations requires further phar-
macogenomic study.
The largest phase III randomized trial comparing pac-
litaxel plus carboplatin treatment with paclitaxel plus cispla-
tin treatment was performed by Rosell et al.22 The study
enrolled 618 patients who received paclitaxel 200 mg/m2 plus
either carboplatin at AUC  6 or cisplatin 80 mg/m2 once
every 3 weeks. In this study, 71% of patients were aged less
than 65 years, with a mean age of 58 years, and 83% of
patients had a performance status of 0 or 1. In contrast, the
mean age of our patients was 76 years, and all patients were
70 years or older; only 56% of our patients had a performance
status of 0 or 1. Median survival was 9.8 months in the
cisplatin arm and 8.5 months in the carboplatin arm in their
study (P  0.05), whereas it was 10.5 and 10.3 months,
respectively, in our study. The response rate was also higher
in our study than theirs. There was no difference in peripheral
neuropathy in their study. Although we used a lower dose of
paclitaxel and cisplatin, peripheral neuropathy occurred more
frequently in our patients who received cisplatin than carbo-
platin, which implies that cisplatin is not a good choice for
elderly patients when paclitaxel is used. However, this com-
bination is appropriate for younger patients, as reported by
Rosell et al.22
Phase II studies (such as ours) usually have a higher
response rate than phase III studies, and older patients fre-
quently have a better response rate than younger patients
when same regimens are used.4 Other phase II studies using
paclitaxel plus carboplatin, either weekly or every 3 weeks,
also showed that this regimen is relatively well tolerated in
elderly patients, with a response rate of approximately 25 to
45% and a median survival time of 9.2 to 14.7 months.23–27 In
addition, a study from Korea with attenuated doses of pacli-
taxel and carboplatin (135 mg/m2 and AUC  5, respec-
tively, every 3 weeks) also showed a good response rate of
40% and median survival of 8.6 months.28
Based on previous studies and this study, treatment
with paclitaxel plus cisplatin induces more peripheral neu-
ropathy than paclitaxel plus carboplatin.10,13 This side effect
is more marked in elderly patients who probably already have
preexisting systemic disease that exacerbates and worsens the
situation. In the present study, we reduced the paclitaxel
dosage in both arms and used a relatively low dose of
TABLE 3. Hematological Toxicity Per Patienta
Toxicity grade
Paclitaxel  carboplatin (%) Paclitaxel  cisplatin (%)
P value*0 1-2 3-4 0 1-2 3-4
Leukopeniab 27.5 57.5 15 26.8 68.2 4.9 0.361
Anemia 10 77.5 12.5 0 90.2 9.8 0.345
Thrombocytopenia 87.5 5 7.5 87.8 9.7 2.4 0.59
aWorst of any course, n  40 in the paclitaxel plus carboplatin arm, n  41 in the paclitaxel plus cisplatin arm.
bTwo patients in the paclitaxel plus carboplatin arm had leukopenic fever and recovered.
*ANOVA test.
TABLE 4. Non-Hematological Toxicity per Patienta
Toxicity grade
Paclitaxel  carboplatin (%) Paclitaxel  cisplatin (%)
P value*0 1 2 3 0 1 2 3
Nausea 80 12.5 7.5 0 75.6 9.8 12.2 2.4 0.379
Vomiting 92.5 5 2.5 0 82.9 0 14.6 2.4 0.249
Peripheral neuropathy 45 32.5 17.5 5 26.8 17.1 53.7 2.4 0.017
Fatigue 65 12.5 20 2.5 12.2 22 48.8 17.1 0.001
Alopecia 57.5 35 7.5 0 19.5 46.3 34.1 0 0.001
aWorst of any course, n  40 in the paclitaxel plus carboplatin arm, n  41 in the paclitaxel plus cisplatin arm. Other toxicities included: one grade 2 mucositis; two grade 1
constipation; three grade 1, two grade 2, one grade 3 diarrhea; four grade 1 and five grade 2 anorexia, one grade 1 renal; three grade 1 and three grade 2 skin rash; and two transient
hypotension in the paclitaxel plus carboplatin arm; and four grade 1 mucositis; six grade 1 and two grade 2 constipation; one grade1 and two grade 2 diarrhea; three grade 1 and
seven grade 2 anorexia, one grade 1 and one grade 3 renal; one grade 2 skin rash; two grade 2 pulmonary, and one spontaneous pneumothorax in the paclitaxel plus cisplatin arm.
*ANOVA test.
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cisplatin, 60 mg/m2 every 3 weeks, which had been demon-
strated to be safe and effective in Chinese patients,29 with the
intention of preventing the occurrence of severe treatment-
related toxicities, especially neuropathy. The patients in the
CIS arm still experienced more fatigue and peripheral neu-
ropathy than those in the CAR arm, whereas other parameters
showed similar therapeutic indexes in both arms. Peripheral
neuropathy and fatigue or weakness are issues deserving of
attention because these effects easily disable or impair the
normal daily activities of elderly patients, who generally
already have some difficulty with mobility and are likely to
be disabled even more by peripheral neuropathy and weak-
ness. Although weakness can improve within 2 weeks after
stopping chemotherapy, neuropathy can last for more than 4
months in our patients. Thus, it is not appropriate to use
paclitaxel with cisplatin in elderly patients.
Other regimens commonly used for elderly patients
include vinorelbine alone or with gemcitabine. Vinorelbine
single-agent treatment is considered a standard regimen for
elderly chemo-naive patients with NSCLC, after the Elderly
Lung Cancer Vinorelbine Italian Study Group and Multi-
center Italian Lung Cancer in the Elderly Study studies
showed its effectiveness.30,31 In addition, neuropathy is not
the main problem when using this agent.
In conclusion, carboplatin, instead of cisplatin, should
be used in elderly patients when combining paclitaxel treat-
ment, because peripheral neuropathy and fatigue occur more
frequently in elderly patients receiving paclitaxel plus cispla-
tin treatment.
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